Evidence map›Paper›PMID 34195264›Full record

ArticleBioMed research international2021

Muhammad Mazhar Fareed, Mohamed A El-Esawi, Enas M El-Ballat, Gaber El-Saber Batiha, Abdur Rauf, Fatma M El-Demerdash, Fahad A Alhumaydhi, Suliman A Alsagaby

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Muhammad Mazhar FareedFaculty of Life Sciences, Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan.ORCID https://orcid.org/0000-0002-6843-7036
Mohamed A El-EsawiBotany Department, Faculty of Science, Tanta University, Tanta 31527, Egypt.ORCID https://orcid.org/0000-0002-8871-5689
Enas M El-BallatBotany Department, Faculty of Science, Tanta University, Tanta 31527, Egypt.ORCID https://orcid.org/0000-0002-2086-5250
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511 AlBeheira, Egypt.ORCID https://orcid.org/0000-0002-7817-425X
Abdur RaufDepartment of Chemistry, University of Swabi, Anbar, KPK, Pakistan.ORCID https://orcid.org/0000-0003-2429-5491
Fatma M El-DemerdashDepartment of Environmental Studies, Institute of Graduate Studies and Research, Alexandria University, Egypt.ORCID https://orcid.org/0000-0001-5624-9145
Fahad A AlhumaydhiDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.ORCID https://orcid.org/0000-0002-0151-8309
Suliman A AlsagabyDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11932, Saudi Arabia.ORCID https://orcid.org/0000-0002-2242-5638
Tanta University · EGAlexandria University · EGDamanhour University · EGGovernment College University, Faisalabad · PKMajmaah University · SAQassim University · SAUniversity of Swabi · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphoglycerate mutase 1 (PGAM1) is considered as a novel target for multiple types of cancer drugs for the upregulation in tumor, cell prefoliation, and cell migration. During aerobic glycolysis, PGAM1 plays a critical role in cancer cell metabolism by catalyzing the conversion of 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG). In this computational-based study, the molecular docking approach was used with the best binding active sites of PGAM1 to screen 5,000 Chinese medicinal phytochemical library. The docking results were three ligands with docking score, RMSD-refine, and residues. Docking scores were -16.57, -15.22, and -15.74. RMSD values were 0.87, 2.40, and 0.98, and binding site residues were Arg 191, Arg 191, Arg 116, Arg 90, Arg 10, and Tyr 92. The best compounds were subjected to ADMETsar, ProTox-2 server, and Molinspiration analysis to evaluate the toxicological and drug likeliness potential of such selected compounds. The UCSF-Chimera tool was used to visualize the results, which shows that the three medicinal compounds named N-Nitrosohexamethyleneimine, Subtrifloralactone-K, and Kanzonol-N in chain-A were successfully binding with the active pockets of PGAM1. The study might facilitate identifying the hit molecules that could be beneficial in the development of antidrugs against various types of cancer treatment. These hit phytochemicals could be beneficial for further investigation of a novel target for cancer.

Indexed as

Antineoplastic AgentsArginineBinding SitesCell MovementCell ProliferationComputer SimulationDrug DesignDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorGlyceric AcidsHumansLigandsMedicine, Chinese TraditionalMolecular Docking SimulationNeoplasmsPhosphoglycerate Mutase2-phosphoglycerate3-phosphoglycerateAntineoplastic AgentsArginineGlyceric AcidsLigandsPhosphoglycerate Mutasephosphoglycerate mutase 1, human

Identifiers

PMID34195264
PMCPMC8184345
OpenAlexW3165890769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.